ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CELZ
BTTC (38) CRIS (27) LIMN (35) PMCB (34) ⌘ Pro Terminal →

Creative Medical Technology Holdings Inc. (CELZ) — RQD Stock Rating Cockpit

$0.62 -4.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.61

Creative Medical Technology Holdings Inc. (CELZ) carries a Roarable Rating of E (Strong Sell) with 20/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CELZ Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CELZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $0.62 (-4.81% 1D, market cap $5.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CELZ ranks #987 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CELZ compare to BTTC and CRIS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CELZ carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of 63.4%, and ROIC of -35.0%. By comparison, BTTC (Black Titan Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $4.8M) and CRIS (Curis Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M). Among the 5-stock peer group, CELZ leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CELZ?
▼

Per CELZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001187953), Creative Medical Technology Holdings Inc. generated $6.0K in revenue (-45.5% YoY), -$6.0M in net income, and -$5.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.61 (-1.06%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (20/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510020
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (3)Whales (5)SEC (3)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.7% Base Target
$5 Bull$1 Base$0 Bear
📬 FREE CELZ RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CELZ)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (20/100 Composite)
🔍 WHY CELZ SCORES 20/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (35% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.6 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+5/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
28
Grade E$0.82-8.5% Next Q
Q2 (-2Q)
25
Grade E$0.75-8% Next Q
Q3 (-1Q)
23
Grade E$0.69-10.1% Next Q
Current
20
Grade E$0.62-11.8% Hist 90D α
Trajectory: E (28) → E (20)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CELZ Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CELZ currently carries a cautious 20/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.91) and Max Pain ($0.65) forces dealer call-delta covering toward $4.96.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CELZ• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CELZ Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 20%NO 80%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
34.630 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.20>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $1$0.62H: $5
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 3 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 9 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CELZ

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (15)

-35.0% ROIC with 63.4% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (18)

Altman-Z 0.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (25)

8/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like CELZ
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CELZ)

  • ✓Walkthrough of CELZ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CELZ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -71.43%▼ DESCENDING CHANNEL
2026-11-03O $0.68H $0.68L $0.62C $0.62VOL 87.3K
RES: $1.01SUP: $-1.04SMA50: $0.91SMA200: $1.56
$5.01$3.82$2.63$1.44$0.25RES $1.01SUP $-1.04$0.622026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CELZ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CELZ Butterfly Map → + Track CELZ →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -45.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CELZ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CELZ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CELZ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CELZ)

Health Care Rank #987 of 1015 ⚔️ BTTC vs CELZ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CELZ vs. BTTC, CRIS, LIMN, PMCB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Creative Medical Technology Holdings Inc. (CELZ) ranks #987 by composite RQD confidence (20/100, grade E) and #943 by equity capitalization ($5.0M). Within this direct 5-issuer industry benchmark cohort, CELZ leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with CELZ at 20/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CELZ ACTIVE
Creative Medical Technology Holdings Inc.
E 20/100 — 63.4% -35.0% -4.81% $5.0M Benchmark Subject
BTTC
Black Titan Corporation
D- 38/100 — — — -3.17% $4.8M /bttc-vs-celz →
CRIS
Curis Inc.
E 27/100 — — -35.0% +10.17% $4.0M /cris-vs-celz →
LIMN
Liminatus Pharma Inc. (Class A)
D- 35/100 — — -35.0% -10.64% $3.8M /limn-vs-celz →
PMCB
PharmaCyte Biotech Inc.
E 34/100 — — -30.2% +2.71% $3.2M /pmcb-vs-celz →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001187953 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Creative Medical Technology Holdings Inc. (CELZ) reported GAAP revenue of $6.0K (-45.5% vs. FY2024 revenue of $11.0K , and -33.3% cumulative change since FY2023) , GAAP net income of -$6.0M, operating cash flow of -$5.9M, and free cash flow of -$5.9M (-10.5% YoY). On the balance sheet, CELZ closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $6.0K -$6.0M -$5.9M -$5.9M $7.8M —
FY2024 (FY) 2024-12-31 $11.0K -$5.5M -$5.3M -$5.3M $6.7M —
FY2023 (FY) 2023-12-31 $9.0K -$5.3M -$8.0M -$8.0M — —

3. CELZ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CELZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $0.62 (-4.81% 1D, market cap $5.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CELZ ranks #987 in composite RQD confidence.

How does CELZ compare to BTTC and CRIS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CELZ carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of 63.4%, and ROIC of -35.0%. By comparison, BTTC (Black Titan Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $4.8M) and CRIS (Curis Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M). Among the 5-stock peer group, CELZ leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CELZ?

Per CELZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001187953), Creative Medical Technology Holdings Inc. generated $6.0K in revenue (-45.5% YoY), -$6.0M in net income, and -$5.9M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CELZ trading relative to its 50-day, 200-day, and 52-week technical levels?

CELZ last traded at $0.62 (-4.81% on volume of 224,683 shares), positioning the stock -31.87% below its 50-day simple moving average ($0.91) and -60.26% below its 200-day simple moving average ($1.56). Across its 52-week range of $0.62 to $4.72, CELZ sits at the 0.0% percentile with a 14-day RSI of 34.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.70).

Direct Sub-Reports: CELZ RQD Cockpit CELZ 12M Forecast CELZ Earnings & Move CELZ Dividends & DRIP CELZ Insiders & 13F CELZ Whale Options CELZ Profit Sankey CELZ News & Why
ROARABLE RATING BRIEF • RQD 20/100 (E) ✓ SEC XBRL & RQD VERIFIED

CELZ — Creative Medical Technology Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Creative Medical Technology Holdings Inc. (CELZ) earns a live Roarable RQD composite score of 20/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.62 (-4.81% 1D, market capitalization $5.0M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 63.4%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Creative Medical Technology Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry..0B as reported in that section. — describes its specific products, customers, or revenue model beyond the sector and industry classification. Revenue is reported as — across the displayed financial periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Creative Medical Technology Holdings Inc. (CELZ) reported $6.0K in annual revenue (up from $11.0K in FY2024, -45.5% YoY) and -$6.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($9.0K revenue, -$5.3M net income) through FY2025, CELZ scaled operating cash flow to -$5.9M and free cash flow to -$5.9M, backed by $7.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 20/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.62 – $4.72 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream suppliers, downstream customers, or sector correlations beyond the Health Care sector and Biotechnology: Biological Products industry classification. An investor should watch whether any future clinical or regulatory developments create dependencies that the current graph does not capture, and whether the Health Care sector and biological products industry trends affect the stock through the Macro Regime Fit pillar's noted sector sensitivity.

  • Key Question #1: Can CELZ sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $6.0K and free cash flow of -$5.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CELZ's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CELZ Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Creative Medical Technology Holdings Inc. (CELZ) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CELZ Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CELZ Bull vs. Bear Conversation Board — What's Your Call at $0.62?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CELZ 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CELZ:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $0.83 (+25.8%)
📌 Pinned Debate

Positive Ultrasome™ pilot data in a 30-person knee osteoarthritis study showed average knee pain scores falling about 65% over six mont

Don't sleep on CELZ's setup in Health Care. Positive Ultrasome™ pilot data in a 30-person knee osteoarthritis study showed average knee pain scores falling about 65% over six months.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (20/100) backs up the fundamental quality.

ArenaChamp_24 🐂 BULL

@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (63.4%) holds, EPS grows into the multiple faster than bears think.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $0.57 (-13.6%)
Spot @ $0.66

With an Altman Z of 0.2, a Piotroski F of 3/9, and ROIC of -35% against zero reported revenue, the forensic profile signals elevated di

Fading this rally in CELZ at $0.66. With an Altman Z of 0.2, a Piotroski F of 3/9, and ROIC of -35% against zero reported revenue, the forensic profile signals elevated distress risk.. With a beta of 1.0 and the stock sitting at $0.66 (52-wk range $0.62–$4.72), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%